Table 2.
Antimicrobial prescriptions in 2016 and 2018 for cases with aURTDa, FLUTDb and abscesses
| Parameter | aURTDa | FLUTDb | Abscesses | ||||
|---|---|---|---|---|---|---|---|
| 2016 | 2018 | 2016 | 2018 | 2016 | 2018 | ||
| Total number of cases | n = 227 | n = 244 | n = 333 | n = 324 | n = 216 | n = 224 | |
| % [CI]c | % [CI]c | % [CI]c | % [CI]c | % [CI]c | % [CI]c | ||
| Antimicrobial treatment | Yesd | 77.1 [71.1–82.4] | 67.6 [61.4–73.5] | 60.1 [54.6–65.4] | 48.8 [43.2–54.4] | 95.8 [92.2–98.1] | 91.5 [87.1–94.8] |
| Details of antimicrobial treatment | n = 175 | n = 165 | n = 200 | n = 158 | n = 207 | n = 205 | |
| % [CI]c | % [CI]c | % [CI]c | % [CI]c | % [CI]c | % [CI]c | ||
| Potentiated aminopenicillin | 40.0 [32.7–47.7] | 49.1 [41.2–57.0] | 60.5 [53.4–67.3] | 69.6 [61.8–76.7] | 63.8 [56.8–70.3] | 63.4 [56.4–70.0] | |
| 3rd generation cephalosporin | 28.0 [21.5–35.3] | 23.6 [17.4–30.9] | 25.5 [19.6–32.1] | 13.9 [8.9–20.3] | 25.1 [19.4–31.6] | 20.5 [15.2–26.7] | |
| Aminopenicillin | 23.4 [17.4–30.4] | 29.1 [22.3–36.7] | 11.5 [7.4–16.8] | 20.9 [14.8–28.1] | 24.2 [18.5–30.6] | 32.2 [25.9–39.1] | |
| Fluoroquinolone | 4.0 [1.6–8.1] | 8.5 [4.7–13.8] | 12.5 [8.3–17.9] | 15.8 [10.5–22.5] | 2.4 [0.8–5.5] | 3.4 [1.4–6.9] | |
| Tetracycline | 16.0 [10.9–22.3] | 20.6 [14.7–27.6] | 0.5 [0.0–2.8] | 0.0 [0.0–2.3] | 0.0 [0.0–1.8] | 0.5 [0.0–2.7] | |
| 1st generation cephalosporin | 0.6 [0.0–3.1] | 0.0 [0.0–2.2] | 3.0 [1.1–6.4] | 1.3 [0.2–4.5] | 5.8 [3.0–9.9] | 9.3 [5.7–14.1] | |
| Otherse | 4.0 [1.6–8.1] | 3.6 [1.3–7.7] | 0.5 [0.0–2.8] | 0.0 [0.0–2.3] | 2.4 [0.8–5.5] | 3.9 [1.7–7.5] | |
| HPCIAsf | Yesd | 33.7 [26.8–41.2] | 33.9 [26.8–41.7] | 38.0 [31.2–45.1] | 29.7 [22.7–37.5] | 27.5 [21.6–34.2] | 23.9 [18.2–30.3] |
| Serial/combination therapy | Yesd | 14.3 [9.5–20.4] | 30.3 [23.4–37.9] | 13.0 [8.7–18.5] | 19.6 [13.7–26.7] | 23.2 [17.6–29.5] | 31.7 [25.4–38.6] |
| Treatment duration (days)g | n = 140 | n = 127 | n = 178 | n = 134 | n = 153 | n = 164 | |
| Median (range) | Median (range) | Median (range) | Median (range) | Median (range) | Median (range) | ||
| 12 (4–37) | 10 (1–21) | 13 (1–56)h | 9.5 (1–42)h | 9 (1–28) | 9 (2–28) | ||
Non-overlapping 95% confidence intervals or comparisons with p-values < 0.05 (for treatment duration) are shown in bold; Data from cases from 2016 has been published previously [45]; aaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract disease; cCI, 95% confidence interval; dValues for the category “no” (reference group) are not shown; eOthers (antimicrobial classes used in ≤ 2% of prescriptions) included amphenicoles, lincosamides, macrolides, penicillins, nitroimidazoles; fHPCIAs, highest priority critically important antimicrobials; gTreatment duration was unknown for numbers not listed (2016: n = 111; 2018: n = 103); hp-value = 0.006